A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06593522
Trial Phases:	Phase II	Protocol IDs:	20230153 (primary) NCI-2024-08984
Eligibility:	18 - 99 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06593522

Summary

The main objective of the study is to characterize safety and efficacy of 2 dose levels
of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded
Independent Central Review (BICR).

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.